We must become aware and begin to address the need for longer term neurological damage having been caused by COVID19. This video outlines the basis for serious concern for the future of many millions of people who are struggling with these conditions. Luckily Quietmind Foundation and our colelagues at Durham University and Neuronic Devices Ltd. are working to foster recognition for the use of intranasal and transcranial infrared photobiomodulation as a simple, low-cost, safe and reliable way for people to help themselves protect against infection, decrease the intensity of the disease and to help mitigate the longer-term neurological damage. We're seeing that about 25% of people worldwide who have been infected with COVID 19 are at risk of developing these longer-term neurological symptoms. Research on the use of 1070nm light stimulation has shown to be effective in helping reduce the effects on brain cells and blood vessels that are the places where the virus is causing damage.
Please listen to Michelle Monje, MD, PhD
Stanford Univ. Neuro-oncologist and Neuroscientist
Then please read the paper below to see how photobiomodulation can be a significant step we all can take to help prevent COVID 19 related injury to ourselves and our family members.
Proteins Involved in Alzheimer's Can 'Overcook' Cells Through Heat
This recent paper from researchers at Cambridge U showed that amyloid buildup in cells increases intracellular temperature that damages cell viability. The idea that a buildup of any kind around something increasing ambient temperature is very reasonable and points to cortical perfusion as a therapeutic target,i.e., increase the system's temperature regulatory capacity.
Spilt, (2008) showed In patients with dementia, cerebral blood flow was 108 mL/min lower than that in subjects of the same age with optimal cognitive function (551 vs 443 mL/min, P < .001). Moore and others at showed the changes in cortical functioning in relation to changes in blood flow. It was also made clear that the function of increased perfusion during neuronal firing was to support temperature regulation, i.e., drawing heat aware to prevent damage.(www.scientificamerican.com/article/blood-flow-may-be-key-player/)
Our efforts at QMF with photobiomodulation (PBM) show that increasing cortical perfusion and vascular flexibility using LED-based transcranial 1070nm photobiomodulation can signiticantly improve motor, cognition and behavioral symptoms of people diagnosed with probable Alzheimer's, FTD, Parkinson's disease and Lewy Body Dementia. I see this as good reason to question the amyloid hypothesis' centrality, i.e., suggesting it is the cause of Alzheimer's and other dementias, given that, 1) the percentage of amyloid plaques within the brains of non-demented age-adjusted individuals had the same percentage of amyloid plaques found within the brains of AD patients , and 2) no relationship was found between the number of amyloid plaques located in the brains of AD patients and their degree of dementia severity [2 (J Alzheimers Dis. 2022; 85(4): 1419–1422.
Clearly amyloid aggregation will increase temperature like a blanket keeps the body warm, however, our primary therapeutic task is to both flush amyloid out of the system by improving glymphatic drainage and improving cortical perfusion thereby reducing overall inflammation and better oxygenate damaged tissue.
Photobiomodulation Therapy and the Glymphatic System: Promising Applications for Augmenting the Brain Lymphatic Drainage System
Article in International Journal of Molecular Sciences · March 2022 DOI: 10.3390/ijms23062975
This is an important resource for those who are working with people diagnosed with neurodegenerative, neuropsychiatric or neurodevelopmental challenges. The key points are that there is a drainage system for the central nervous system that can become blocked and this leads to development of cognitive and behavioral symptoms associated with neurodegenerative disorders, including Alzheimer's and Parkinson's disease. The glial cells that support and protect the neurons are supported by this system to provide a way to discharge waste products from the brain. Sleep has now been shown to be the key driver in supporting the efficient operation of the glymphatic system.
Photobiomodulation is now been shown to positively influence the glymphatic processes by improving cortical perfusion and oxygenation as well as improving vascular flexibility of the brain's microcapillary system and acts to maintain, protect and optimize the clearance of neural waste products. Previous research has demonstrated that 1064nm stimulation is significantly more effective than 810nm wavelength at producing specific biological activity that is associated with both perfusion and tissue level oxygenation as well as improving cellular energy metabolism by increasing production of adenosine triphosphate (ATP) through accelerating neural and glial cell mitochondrial activation.
The Neuradiant 1070 PBM helmet selectively delivers cortical 1070nm LED light stimulation to specific brain regions and can thereby provide effective penetration and cellular activation thus supporting the glymphatic drainage process. For more information on the Neuradiant 1070 see neuronic.online
We've sold about 170 units over the last 16 months and I'm impressed by the number of people who are reporting rather quick positive response to using the new model Neuradiant 1070 4Q transcranial photobiomodulation system. The most common response has been improved sleep and decreased brain fog which has been among the top 5 most often reported areas of change from previous users of the 1070nm stimulation. We've had 3 returns of the total number sold which is a testament to the value folks are seeing in using this technology.
Clinicians like Rick Abbey, Ph.D a neuropsychologist in Palo Alto have noted on social media and in personal discussions that his clients are regularly reporting positive responses to using the Neuradiant units in their efforts to overcome a wide range of cognitive, behavioral and learning-based challenges. The team at Neuronic are noting testimonials appearing on on Trust Pilot acknowledging the ease of use and rapid changes in functioning among users of the new 1070 4Q system. I've even been called by family members who used the unit on their loved ones to report remarkable almost immediate changes in focus and attention and verbal behavior who were in very advanced stages of dementia. This is not all that unusual if you think about neurodegeneration as a failing battery's ability to hold a charge. So, if you infuse the battery with a strong charge using high levels of concentrated sunlight, you reinvigorate it's ability to drive activities that required more 'juice' than it could previously deliver. The more often you boost the battery (brain tissue) with this type of charge, the more flexible and capable it becomes at holding the charge for longer periods of time.
If you then add neurofeedback training to the protocol you are then upgrading the wiring system that supports the transmission of the power to all the other systems in the body with a corresponding overall functional improvement in cognition,, movement, and self expression. Our work now is on integrating these functions more efficiently wherein we'll drive the stimulation based on changes in the overall central nervous system's functional efficiency.
We're getting there.
COVID ups risks of dementia, cognitive impairment, and decline in older survivorsSadly and not surprisingly, the science media is reporting that the neurological impact of covid 19 is showing increased levels of cognitive decline worldwide. Older adults are having to cope with damage to their lungs and central nervous system. The study noted that the telephone survey measures used were limited in identifying more specific challenges and likely underestimate the size of the problem due to having excluded subjects with any family history of dementia. The global dementia care burden is likely to be greater as a result of the COVID-19 pandemic and so there is even greater need to rapid intervention now that can be easily, safely and cost effectively deployed. Researchers and clinicians at Quietmind Foundation, Neuronic Devices Ltd (Neuronic.online), Baylor Research Institute and the Biophotonic and Neuroimaging Lab•UTexas-Arlington are collaborating to show the effectiveness of self-administered, transcranial infrared light-based therapy to reduce dementia's cognitive and behavioral symptoms.
The Neuradiant 1070 4Q technology that's being released this month by Neuronic Devices Ltd. (see Neuronic.online) is a resource that can address the debilitating impact of COVID 19 on the brain by increasing cortical perfusion and ATP production by stimulating cytochrome c oxidase and improving blood vessel flexibility. In addition, the new independent 4 -quadrant control of pulse frequency allows for renormalization of dysregulated brain network connectivity using the light pulsations to directly changes in EEG activity.
Mental disorders in early life are associated with a significantly increased risk of dementia in later years.
Our team regularly publishes articles and blog posts on the latest research and news coming out of our group and the field in general.